OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma
OS Therapies' subsidiary OS Animal Health received USDA feedback on its conditional licensure pathway for OST-HER2 in canine osteosarcoma, covering efficacy, safety, non-clinical, and CMC requirements. OSAH plans to seek conditional licensure on existing clinical data and hopes for a 2027 U.S. commercial launch, though full licensure will require additional studies. The company is also evaluating strategic and capital alternatives for OSAH, including a Q4 2026 crowdfunding intended to help the subsidiary meet U.S.
Key figures
- Drug Name
- OST-HER2
- Vet oncology market 2024
- $1.58 billion
- Vet oncology market 2034
- $4.77 billion
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.